301103 何氏眼科
午间休市 01-15 11:30:00
资讯
新帖
简况
何氏眼科:坚持聚焦主业稳健经营
证券之星 · 01-12 20:48
何氏眼科:坚持聚焦主业稳健经营
何氏眼科:审慎推进并购重组
证券之星 · 01-12 20:48
何氏眼科:审慎推进并购重组
何氏眼科:坚定看好中国眼科行业长期发展前景
证券之星 · 01-09
何氏眼科:坚定看好中国眼科行业长期发展前景
何氏眼科:将根据资金安排考量回购计划
证券之星 · 01-08
何氏眼科:将根据资金安排考量回购计划
何氏眼科:沈阳爱络博智能科技从事眼科器械研发
证券之星 · 01-07
何氏眼科:沈阳爱络博智能科技从事眼科器械研发
何氏眼科:股东健康回馈活动将长期落地执行
证券之星 · 2025-12-30
何氏眼科:股东健康回馈活动将长期落地执行
何氏眼科(301103)披露股东回馈活动公告,12月26日股价下跌0.71%
证券之星 · 2025-12-26
何氏眼科(301103)披露股东回馈活动公告,12月26日股价下跌0.71%
何氏眼科最新公告:开展投资者健康回馈活动
证券之星 · 2025-12-26
何氏眼科最新公告:开展投资者健康回馈活动
何氏眼科(301103)披露召开2026年第一次临时股东会通知,12月25日股价上涨0.87%
证券之星 · 2025-12-25
何氏眼科(301103)披露召开2026年第一次临时股东会通知,12月25日股价上涨0.87%
何氏眼科:坚持聚焦主业稳健经营
证券之星 · 2025-12-24
何氏眼科:坚持聚焦主业稳健经营
股市必读:何氏眼科(301103)12月22日董秘有最新回复
证券之星 · 2025-12-23
股市必读:何氏眼科(301103)12月22日董秘有最新回复
何氏眼科:集成智能辅助诊断系统
证券之星 · 2025-12-22
何氏眼科:集成智能辅助诊断系统
何氏眼科:公司在各期定期报告中会披露对应时点的股东信息
证券日报 · 2025-12-11
何氏眼科:公司在各期定期报告中会披露对应时点的股东信息
何氏眼科:整合智能算法辅助诊断系统
证券之星 · 2025-12-10
何氏眼科:整合智能算法辅助诊断系统
何氏眼科:何星儒将依法合规推进市值管理
证券之星 · 2025-12-10
何氏眼科:何星儒将依法合规推进市值管理
何氏眼科:公司高度重视股东利益
证券之星 · 2025-12-08
何氏眼科:公司高度重视股东利益
何氏眼科(301103)披露2025年限制性股票激励计划首次授予结果,12月5日股价上涨0.91%
证券之星 · 2025-12-05
何氏眼科(301103)披露2025年限制性股票激励计划首次授予结果,12月5日股价上涨0.91%
何氏眼科:精准医疗与抗衰老已有技术储备和布局
证券之星 · 2025-12-03
何氏眼科:精准医疗与抗衰老已有技术储备和布局
何氏眼科:公司不排除投资AI眼镜企业的可能性
证券之星 · 2025-12-03
何氏眼科:公司不排除投资AI眼镜企业的可能性
何氏眼科:部分门店引入雷鸟智能眼镜销售
证券之星 · 2025-12-03
何氏眼科:部分门店引入雷鸟智能眼镜销售
加载更多
公司概况
公司名称:
辽宁何氏眼科医院集团股份有限公司
所属行业:
卫生
上市日期:
2022-03-22
主营业务:
辽宁何氏眼科医院集团股份有限公司的主营业务是向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要产品是眼科专科诊疗服务和视光服务。
发行价格:
42.50
{"stockData":{"symbol":"301103","market":"SZ","secType":"STK","nameCN":"何氏眼科","latestPrice":21.27,"timestamp":1768448985000,"preClose":21.46,"halted":0,"volume":1225695,"delay":0,"changeRate":-0.0089,"floatShares":122000000,"shares":158000000,"eps":0.0673,"marketStatus":"午间休市","change":-0.19,"latestTime":"01-15 11:30:00","open":21.4,"high":21.63,"low":21.18,"amount":26226900,"amplitude":0.021,"askPrice":21.29,"askSize":3,"bidPrice":21.27,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.0673,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768453200000},"marketStatusCode":3,"adr":0,"adjPreClose":21.46,"symbolType":"stock","openAndCloseTimeList":[[1768440600000,1768447800000],[1768453200000,1768460400000]],"highLimit":23.61,"lowLimit":19.31,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":158026471,"isCdr":false,"pbRate":1.78,"roa":"--","peRate":316.047548,"roe":"2.87%","epsLYR":-0.1734,"committee":-0.577778,"marketValue":3361000000,"turnoverRate":0.0101,"status":1,"floatMarketCap":2587000000},"requestUrl":"/m/hq/s/301103","defaultTab":"news","newsList":[{"id":"2602517929","title":"何氏眼科:坚持聚焦主业稳健经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517929?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:48","pubTimestamp":1768222100,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科01月12日在投资者关系平台上答复投资者关心的问题。公司坚信,长期稳定的市值源于扎实的经营业绩与清晰的价值逻辑。未来,公司坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通,稳步推进资本市场品牌建设,努力为投资者创造长期价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200034403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2602179115","title":"何氏眼科:审慎推进并购重组","url":"https://stock-news.laohu8.com/highlight/detail?id=2602179115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602179115?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:48","pubTimestamp":1768222099,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科(301103)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问:公司收购并购能不能既考虑盈利性,又考虑题材概念性?何氏眼科回复:尊敬的投资者您好, 在并购战略层面,公司遵循业务协同、战略协同、风险可控的原则。未来,公司将结合行业发展趋势、自身经营需求及标的资产质量,审慎推进并购重组。若后续有相关计划达到信息披露标准,将严格按照法律法规要求及时履行披露义务,切实维护全体股东利益。敬请谨慎决策、注意投资风险。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200034401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236","161123"],"gpt_icon":0},{"id":"2602437508","title":"何氏眼科:坚定看好中国眼科行业长期发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2602437508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602437508?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:51","pubTimestamp":1767963107,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科01月08日在投资者关系平台上答复投资者关心的问题。上述事项对公司当前主营业务开展或业绩未造成重大影响,敬请谨慎决策、注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2601364955","title":"何氏眼科:将根据资金安排考量回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601364955?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:51","pubTimestamp":1767876678,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科(301103)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司之前在股价25左右曾经大幅回购股票,为何目前在20附近却不果断出手回购呢?目前股价处于低位,建议公司管理层果断出手维护市场稳定!何氏眼科回复:尊敬的投资者您好,对于您提及的相关举措,公司管理层将根据公司资金安排并结合实际经营情况及未来发展需求等多种因素考量,未来如有回购相关计划,将严格按照法律法规及交易所规则,履行决策程序并及时披露相关信息。感谢您的建议。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800036915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2601878496","title":"何氏眼科:沈阳爱络博智能科技从事眼科器械研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878496?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:18","pubTimestamp":1767773907,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科(301103)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司的关联公司沈阳爱络博智能科技有限公司在脑机接口领域有哪些布局?何氏眼科回复:尊敬的投资者您好,沈阳爱络博智能科技有限公司为公司实际控制人控制的关联企业,并非公司直接参股公司。其主要从事眼科相关医疗器械、智能软硬件系统的研发、生产与销售。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700021359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2595817763","title":"何氏眼科:股东健康回馈活动将长期落地执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2595817763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595817763?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:36","pubTimestamp":1767065768,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月29日在投资者关系平台上答复投资者关心的问题。感恩每一份信任,何氏眼科将始终坚守 “守护全民眼健康” 的初心,以扎实发展回馈股东、回馈社会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2594014294","title":"何氏眼科(301103)披露股东回馈活动公告,12月26日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594014294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594014294?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:58","pubTimestamp":1766761094,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,何氏眼科报收于19.54元,较前一交易日下跌0.71%,最新总市值为30.88亿元。该股当日开盘19.67元,最高19.81元,最低19.48元,成交额达2418.91万元,换手率为0.78%。同日,公司发布《关于股东回馈活动的自愿性信息披露公告》,宣布为庆祝成立三十周年,将开展“投资者健康回馈活动”。活动由公司下属分院及核心城市门诊执行,自公告发布之日起长期实施。公告中提及,本次活动不影响公司经营状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2594826747","title":"何氏眼科最新公告:开展投资者健康回馈活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2594826747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594826747?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:57","pubTimestamp":1766739437,"startTime":"0","endTime":"0","summary":"何氏眼科(301103.SZ)公告称,公司成立三十周年之际,为感谢投资者的长期信任,开展“投资者健康回馈活动”。活动内容包括为股东配备专属眼健康服务顾问,提供视光产品类、诊疗项目专属优惠,近视矫正屈光手术股东专属优惠,医美项目以及眼健康检查专属方案。活动范围包括现有股东、历史股东及未来投资者,以及股东本人及直系亲属。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600023803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2594308952","title":"何氏眼科(301103)披露召开2026年第一次临时股东会通知,12月25日股价上涨0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594308952","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594308952?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:54","pubTimestamp":1766674458,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘,何氏眼科报收于19.68元,较前一交易日上涨0.87%,最新总市值为31.1亿元。该股当日开盘19.57元,最高19.75元,最低19.45元,成交额达2326.23万元,换手率为0.75%。公司近日发布公告,宣布将于2026年1月14日召开2026年第一次临时股东会,会议由董事会召集,现场会议地点位于辽宁省沈阳市皇姑区黄河南大街118号甲泰和国际大厦15楼。股权登记日为2026年1月7日。股东可通过现场或网络投票方式参与会议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2593723284","title":"何氏眼科:坚持聚焦主业稳健经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2593723284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593723284?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:51","pubTimestamp":1766580703,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月23日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400037414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2593852430","title":"股市必读:何氏眼科(301103)12月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593852430","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593852430?lang=zh_cn&edition=full","pubTime":"2025-12-23 03:55","pubTimestamp":1766433315,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘,何氏眼科报收于19.75元,下跌0.95%,换手率0.79%,成交量1.25万手,成交额2474.39万元。此外,何氏眼科“光明小屋”以智能眼科设备为入口,结合线上线下诊疗体系,通过智能诊断技术筛查眼部疾病及相关慢性病,打造数字技术赋能的基层眼健康管理场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300003038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2593041031","title":"何氏眼科:集成智能辅助诊断系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2593041031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593041031?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:24","pubTimestamp":1766388264,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月22日在投资者关系平台上答复投资者关心的问题。此外,何氏眼科“光明小屋”以智能眼科设备为入口,结合线上线下诊疗体系,通过智能诊断技术筛查眼部疾病及相关慢性病,打造数字技术赋能的基层眼健康管理场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200012498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2590513677","title":"何氏眼科:公司在各期定期报告中会披露对应时点的股东信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513677","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590513677?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:34","pubTimestamp":1765452840,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月11日,何氏眼科在互动平台回答投资者提问时表示,为保证所有投资者公平地获取公司的信息,公司在各期定期报告中会披露对应时点的股东信息。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhamthc8026918.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhamthc8026918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2590745582","title":"何氏眼科:整合智能算法辅助诊断系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2590745582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590745582?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:51","pubTimestamp":1765371109,"startTime":"0","endTime":"0","summary":"何氏眼科回复:尊敬的投资者您好,公司在智能化系统眼科应用方面,整合了智能算法辅助诊断系统,建设眼科专科智能影像云平台,开发多模态数据融合决策系统,并生成3D眼健康数字孪生模型。此外何氏眼科“光明小屋”以眼科智能设备为入口,结合线上和线下的眼科诊疗系统,通过先进的智能诊断,发现眼部疾病和慢性疾病,打造数字智能技术赋能基层眼健康管理的数字场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000037911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2590372250","title":"何氏眼科:何星儒将依法合规推进市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590372250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590372250?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:36","pubTimestamp":1765337784,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科(301103)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问何星儒何总新官上任,有改变公司上市以来一直处于股价破发的计划吗?何氏眼科回复:尊敬的投资者您好,公司股价受多重因素综合影响,何星儒先生作为新任总经理将全面负责公司日常经营管理事务,致力于提升公司业绩与内在价值,并将根据市场情况和监管要求,依法合规推进市值管理工作。感谢您对公司的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000013994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2589338541","title":"何氏眼科:公司高度重视股东利益","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338541?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:00","pubTimestamp":1765180828,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月08日在投资者关系平台上答复投资者关心的问题。关于股东福利的建议,公司高度重视股东利益,会考虑通过多种方式回馈股东,包括但不限于提供公司产品和服务的体验机会,以彰显公司实力、提升品牌形象,同时为股东创造实际价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800013888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2589626813","title":"何氏眼科(301103)披露2025年限制性股票激励计划首次授予结果,12月5日股价上涨0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589626813","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589626813?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:31","pubTimestamp":1764945089,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘,何氏眼科报收于20.06元,较前一交易日上涨0.91%,最新总市值为31.7亿元。该股当日开盘19.88元,最高20.1元,最低19.63元,成交额达2547.83万元,换手率为0.81%。同日,公司发布公告称,已于2025年12月5日向240名核心管理人员及核心骨干首次授予510.00万股第二类限制性股票,授予价格为13.00元/股。本激励计划有效期最长不超过60个月,首次授予部分分三年归属,归属比例分别为30%、30%、40%。本次授予不会导致公司股权分布不符合上市条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2588401350","title":"何氏眼科:精准医疗与抗衰老已有技术储备和布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2588401350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588401350?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:27","pubTimestamp":1764746838,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月03日在投资者关系平台上答复投资者关心的问题。精准医疗方面,公司下属沈阳何氏眼科医院开设了遗传门诊,开展遗传眼病基因检测、高度近视风险筛查等服务,形成基因治疗全生命周期防控体系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300018058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2588013323","title":"何氏眼科:公司不排除投资AI眼镜企业的可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=2588013323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588013323?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:21","pubTimestamp":1764746482,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月03日在投资者关系平台上答复投资者关心的问题。关于您提及的领域,公司不排除此类投资的可能性,但具体的投资决策需要根据市场情况和公司战略规划来定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300018011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2588018071","title":"何氏眼科:部分门店引入雷鸟智能眼镜销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2588018071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588018071?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:18","pubTimestamp":1764746304,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科12月03日在投资者关系平台上答复投资者关心的问题。该合作系基于市场需求的常规业务布局,对公司财务状况及经营成果未构成重大影响。未来,若双方合作涉及重大事项达到信息披露标准,公司将严格按照监管要求及时履行信息披露义务,敬请投资者理性投资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300017981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768448999817,"stockEarnings":[{"period":"1week","weight":0.0746},{"period":"1month","weight":0.1108},{"period":"3month","weight":0.0322},{"period":"6month","weight":-0.0649},{"period":"1year","weight":0.1322},{"period":"ytd","weight":0.0938}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁何氏眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"9888人(较上一季度减少8.55%)","perCapita":"12301股","listingDate":"2022-03-22","address":"辽宁省沈阳市浑南区天赐街5-1号(607)","registeredCapital":"15802万元","survey":" 辽宁何氏眼科医院集团股份有限公司的主营业务是向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要产品是眼科专科诊疗服务和视光服务。","listedPrice":42.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"何氏眼科,301103,何氏眼科股票,何氏眼科股票老虎,何氏眼科股票老虎国际,何氏眼科行情,何氏眼科股票行情,何氏眼科股价,何氏眼科股市,何氏眼科股票价格,何氏眼科股票交易,何氏眼科股票购买,何氏眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}